-

12:33:53 AM

ALDX Stock News

ALDX - Aldeyra Therapeutics Inc

03/02/21 8:00 AM

Nasdaq : ALDX

conferences

Aldeyra Therapeutics to Participate in Upcoming Virtual Investor Conferences

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that President and Chief Executive Officer Todd C. Brady, M.D., Ph.D. will participate in analyst-led fireside conversations at the H.C. Wainwright Global Life Sciences Conference and the Oppenheimer 31st Annual Healthcare

RHEA-AI

neutral

02/18/21 8:00 AM

Nasdaq : ALDX

conferences

Aldeyra Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will present at the 10th Annual SVB Leerink Global Healthcare Conference at 3:40 p.m. ET Friday, February 26, 2021.A live webcast of the presentation will be

RHEA-AI

neutral

02/04/21 8:00 AM

Nasdaq : ALDX

clinical trial

Aldeyra Therapeutics Announces Phase 3 TRANQUILITY Dry Eye Disease Trial Design

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases, today announced the finalization of the design of the Phase 3 TRANQUILITY

RHEA-AI

neutral

01/20/21 7:00 AM

Nasdaq : ALDX

offering

Aldeyra Therapeutics, Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases, today announced the closing of its underwritten public offering of 7,868,421

RHEA-AI

neutral

01/13/21 9:36 PM

Nasdaq : ALDX

offering

Aldeyra Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases, today announced the pricing of an underwritten public offering of 6,842,106

RHEA-AI

neutral

01/13/21 4:01 PM

Nasdaq : ALDX

offering

Aldeyra Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases, today announced that it intends to offer and sell, subject to market and other

RHEA-AI

neutral

01/08/21 8:00 AM

Nasdaq : ALDX

conferences

Aldeyra Therapeutics to Participate in Fireside Chat at the H.C. Wainwright BioConnect 2021 Virtual Conference

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright BioConnect 2021 Virtual Conference.The fireside chat will be available beginning at 6:00 a.m. ET

RHEA-AI

neutral

01/07/21 7:00 AM

Nasdaq : ALDX

clinical trial

Aldeyra Therapeutics Announces Positive Top-Line Symptom and Sign Results from Run-In Cohort of Phase 3 TRANQUILITY Trial in Dry Eye Disease

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced positive top-line symptom, redness, and Schirmer’s test results from the run-in cohort of the Phase 3 TRANQUILITY clinical trial in patients with dry eye disease.The double-masked, single-center, parallel-group run-in cohort

RHEA-AI

neutral

01/06/21 4:30 PM

Nasdaq : ALDX

conferencesclinical trial

Aldeyra Therapeutics to Host Conference Call and Webcast to Discuss Top-Line Symptom, Redness, and Schirmer’s Test Results from Run-in Cohort of Phase 3 TRANQUILITY Trial

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host a conference call and webcast at 8:00 a.m. ET Thursday, January 7, 2021, to discuss top-line symptom, redness, and Schirmer’s test results from the run-in cohort of the Phase 3 TRANQUILITY clinical trial in patients with dry eye disease.

RHEA-AI

neutral

12/22/20 8:00 AM

Nasdaq : ALDX

Aldeyra Therapeutics Announces Confirmation of Antiviral Activity of ADX-1612

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced confirmation of SARS-CoV-2 antiviral activity of ADX-1612, in addition to novel anti-inflammatory activity in SARS-CoV-2-infected primary human cells in preclinical studies. The results are derived from an international

RHEA-AI

neutral

Prev 1 2 3 4 5 6 Next

ALDX Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.aldeyra.com
Security nameAldeyra Therapeutics Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees11
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing

About Aldeyra Therapeutics Inc

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead investigational compounds, reproxalap and ADX-629, target RASP (reactive aldehyde species), which are elevated in ocular and systemic inflammatory disease and result in cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in development for COVID-19 and ovarian cancer.